Thus, the increasing understanding of the role of various BCL-2 family members in regulating non-canonical functions in mitochondrial processes may allow to develop drugs, which could either prevent mitochondria-dependent necrotic cell death and thereby support tissue integrity, or on the contrary boost CICD to render cancer therapy more effective (Figure 3). This evidence concerns the gene BCL2 and cancer.